BIIB059 in healthy Japanese subjects

Phase 1, randomised, double-blind trial of litifilimab in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (4 arms), sponsored by Biogen. Primary endpoints: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 20 weeks, Percentage of Participants With Clinically Significant Abnormal Clinical Laboratory Parameters, Vital Signs, 12-Lead Electrocardiograms (ECG), and Physical Examination Findings up to 20 weeks and 1 more. Started Oct 2017; status: completed.